A New Chapter for Gene Editing: Scribe Therapeutics Takes Nasdaq by Storm with Upsized IPO

Well, this is certainly a moment worth noting for the biotech world! Scribe Therapeutics, that innovative California-based firm pushing the boundaries of gene editing, just made a rather impressive splash on the Nasdaq. They successfully priced an upsized initial public offering, raking in approximately $128.7 million. This isn't just any IPO; it's a significant vote of confidence for a company co-founded by none other than Jennifer Doudna, the Nobel laureate and co-inventor of CRISPR gene editing technology.

Trading under the ticker SCTX, Scribe saw its shares hit the Nasdaq Global Market on Friday, July 25, 2026, after pricing on Thursday. The company sold a solid 8.58 million shares, a notable increase from the initial suggestion of 7.1 million, all at a price of $15.00 each. That's right, they priced at the very top of their marketed range of $13-$15 per share. It seems the market was genuinely eager for a piece of this action, with the offering officially set to close on July 27, 2026.

Beyond the impressive financial figures, it's the caliber of the team that truly stands out. You have Jennifer Doudna, of course, a true luminary in the field. But she's joined by CEO Benjamin Oakes and co-founder Brett Staahl, forming a formidable trio aiming to harness the power of CRISPR. Their vision? To develop in vivo gene-editing therapies that can be delivered directly into the body, a monumental step forward for treating complex diseases.

So, what exactly is Scribe going to do with all that freshly raised capital? The plan, as articulated by the company, is to strategically advance its ambitious in vivo CRISPR gene-editing pipeline. Specifically, these funds are earmarked for moving therapies aimed at cardiometabolic diseases through clinical development, right up to those crucial data readouts that investors (and patients!) are eagerly awaiting.

Speaking of the pipeline, let's talk about their lead candidate, STX-1150. This therapy utilizes Scribe's proprietary ELXR epigenetic editing platform to silence the PCSK9 gene, which in turn is designed to lower LDL cholesterol – often dubbed the "bad" cholesterol. It's a big deal, and perhaps most excitingly, STX-1150 recently entered a Phase I trial in Australia. The biotech community will certainly be keeping a close eye out for topline data, which is anticipated in the first half of 2027.

But STX-1150 isn't the only horse in their race. Scribe also has a couple of earlier-stage candidates, STX-1200 and STX-1400, both leveraging their innovative XE CRISPR platform. STX-1200 is designed to target LPA for lipoprotein(a) reduction, while STX-1400 is taking aim at APOC3 to address severe hypertriglyceridemia. Both are currently in preclinical development, with planned Phase I studies slated for 2027 and 2028, respectively. It’s clear they have a robust and well-thought-out strategy.

It certainly helps that Scribe isn't flying solo here. They've already forged strong relationships with pharmaceutical giants like Eli Lilly and Sanofi, boasting research collaborations potentially worth over $2 billion in total biobuck commitments. And in a further show of confidence, Sanofi agreed to snap up 500,000 shares at the IPO price in a concurrent private placement, adding another $7.5 million to Scribe's coffers. Major stockholders prior to the IPO included a16z, Eli Lilly, and Avoro, alongside the founders themselves. Leading the charge on the underwriting side were Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities.

This IPO really is a landmark, marking the first time a gene-editing company has gone public in over two years, since Metagenomi's offering back in February 2024. Scribe Therapeutics first emerged on the scene in 2020, backed by $20 million and an early partnership with Biogen. Fast forward to today, and they’re positioned to make a truly significant impact on medicine. With this successful funding round, they're not just raising capital; they're fueling the future of gene editing, aiming to translate groundbreaking science into real-world patient benefits.